City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Mihaela Cristea, MD  
Search results:  9  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-9 Trials Jump to page:

COH Protocol Number: 17095 ClinicalTrials.gov Number: NCT02539719

Principal Investigator: Mihaela Cristea, MD
Sponsor: Industrial

Title:  A Phase 1a/1b Dose Escalation and Expansion Study of Single-Agent SC-003 in Subjects with Platinum-Resistant/Refractory Ovarian Cancer

COH Protocol Number: 16294 ClinicalTrials.gov Number: NCT02996825

Principal Investigator: Mihaela Cristea, MD
Sponsor: Institutional

Title:  A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients with FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)

COH Protocol Number: 16171 ClinicalTrials.gov Number: NCT02853604

Principal Investigator: Mihaela Cristea, MD
Sponsor: Industrial

Title:  Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

COH Protocol Number: 15056 ClinicalTrials.gov Number: NCT02419417

Principal Investigator: Mihaela Cristea, MD
Sponsor: Industrial

Title:  A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors

COH Protocol Number: 15014 ClinicalTrials.gov Number: NCT02101775

Principal Investigator: Mihaela Cristea, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-131, NCI#9568: A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with AZD 1775 (MK 1775) in Women with Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

COH Protocol Number: 13204 ClinicalTrials.gov Number: NCT00719303

Principal Investigator: Mihaela Cristea, MD
Sponsor: Cooperative Group

Title:  GOG-0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

COH Protocol Number: 12291 ClinicalTrials.gov Number: NCT01567891

Principal Investigator: Mihaela Cristea, MD
Sponsor: Industrial

Title:  A Phase I/IIa, Open Label, Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1/LAGE-1 in Patients with Recurrent or Treatment Refractory Ovarian Cancer

COH Protocol Number: 09188 ClinicalTrials.gov Number: NCT00978250

Principal Investigator: Mihaela Cristea, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-94, NCI#8351: Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd+THU)

COH Protocol Number: 07187

Principal Investigator: Mihaela Cristea, MD
Sponsor: Institutional

Title:  Evaluation of Ovarian Cancer and Outcomes of Care

 
Results per page: 25 50 100 All 1-9 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.